OBJECTIVES: The aim of our study is to analyse the biosimilar bids of the Hungarian National Health Insurance Fund Administration in case of erythropoietin (ESA) products. METHODS: Data derived from the nationwide pharmaceutical database of Hungarian National Health Insurance Fund Administration. We analysed how the number of patients treated by erythropoietin products changed before (01.07.2011.-30.06.2012.) and after (01.07.2012.-30.06.2013.) the first biosimilar bid performed in March 2012 in Hungary. RESULTS: In the 12 months before biosimilar bid 4,482 patients received erythropoietin treatment, while in the first 12 months after the bid 4,545 patients, resulting in a 1.4 % increase. The second 12 months after the bid 4,644 patients received erythropoietin treatment, resulting in a 3.6 % increase. Before the biosimilar bid, the NHIFA spent 2.33 billion Hungarian Forint (HUF) health insurance reimbursement for ESA products, which decreased by 47 % to 1.23 billion HUF in the first year after biosimilar bid. CONCLUSIONS: The analyses of the Hungarian price competition bid of biosimilar products showed a minimal decline in the number of patients under treatment by erythropoietin products while the health insurance reimbursement of these drugs significantly decreased.